Latest News - Acquisitions and Mergers

Wednesday, January 18, 2017 | Acquisitions and Mergers, Headache & Pain, Personnel/Company News

Lilly to Acquire Migraine Drug Maker CoLucid

Eli Lilly and Co. is set to acquire CoLucid Pharmaceuticals for $960 million. CoLucid is currently developing lasmiditan, a migraine medicine that could help patients with cardiovascular disease.…

Read the full story

Monday, November 23, 2015 | Acquisitions and Mergers, Business of Medicine

Pfizer and Allergan to Combine

The boards of directors for Pfizer Inc. and Allergan plc have both unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allerga…

Read the full story

Monday, November 17, 2014 | Acquisitions and Mergers

Valeant Comments On Allergan Announcement

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement un…

Read the full story

Monday, November 17, 2014 | Acquisitions and Mergers

Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue

Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash…

Read the full story

Wednesday, September 24, 2014 | Acquisitions and Mergers

Acorda Therapeutics to Acquire Civitas Therapeutics

Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301,…

Read the full story

Wednesday, June 18, 2014 | Acquisitions and Mergers

Valeant Commences Exchange Offer For Allergan

Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), …

Read the full story

Tuesday, June 10, 2014 | Acquisitions and Mergers

Allergan Again Unanimously Rejects Valeant’s Revised Unsolicited Proposal

Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced T…

Read the full story

Monday, June 02, 2014 | Acquisitions and Mergers

Allergan Comments on Pershing Square's and Valeant's Attempt to Remove a Majority of the Members of the Allergan Board of Directors

Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today issued the following statement regarding the filing by Pershing Square Capital Management, L.P. ("Pershing Square") of preliminary proxy …

Read the full story

Friday, May 30, 2014 | Acquisitions and Mergers

Valeant Takes Steps in Pursuit of Allergan

Valeant has increased its bid for Allergan, announcing today a new deal valued at $72 per share. This is the latest of several steps by Valeant in its pursuit of the Botox maker. In a deal valued at $…

Read the full story

Friday, May 30, 2014 | Acquisitions and Mergers

Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations

Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchan…

Read the full story

Wednesday, May 21, 2014 | Acquisitions and Mergers

Allergan Physician Customers Voice Strong Support Following Allergan's Rejection of Unsolicited Proposal to Acquire Company

Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that it has received a strong outpouring of support from its physician customers, their nurses and office staff members, as wel…

Read the full story

Tuesday, February 19, 2013 | Acquisitions and Mergers

Allergan to Buy Map Pharmaceuticals

Botox maker Allergan, Inc. has moved to buy Map Pharmaceuticals for $958 million to gain the experimental inhalable migraine treatment Levadex. Map is currently seeking approval for the drug—an inha…

Read the full story